Information Provided By: 
Fly News Breaks for April 29, 2019
SILK
Apr 29, 2019 | 05:27 EDT
BMO Capital analyst Joanne Wuensch started Silk Road Medical with an Outperform rating and $45 price target. Silk Road's Enroute TCAR system follows the "classic transition from open to minimally invasive procedure," Wuensch tells investors in a research note. She believes TCAR should become the new standard of care. "Simply put, there is a long runway ahead of it," says the analyst.
News For SILK From the Last 2 Days
There are no results for your query SILK
